Human Epidermal Growth Factor Receptor 2-positive (HER2 + ) breast cancer (BC) is a highly aggressive disease commonly treated with chemotherapy and anti-HER2 drugs, including trastuzumab. There is currently no way to predict which HER2 + BC patients will benefit from these treatments. Previous prognostic signatures for HER2 + BC were developed irrespective of the subtype or the hierarchical organization of cancer in which only a fraction of cells, tumor-initiating cells (TICs), can sustain tumor growth. Here, we used serial dilution and single-cell transplantation assays to identify MMTV-Her2/Neu mouse mammary TICs as CD24
− at a frequency of 2-4.5%. A 17-gene Her2-TICenriched signature (HTICS), generated on the basis of differentially expressed genes in TIC versus non-TIC fractions and trained on one HER2 + BC cohort, predicted clinical outcome on multiple independent HER2 + cohorts. HTICS included up-regulated genes involved in S/G2/ M transition and down-regulated genes involved in immune response. Its prognostic power was independent of other predictors, stratified lymph node + HER2 + BC into low and high-risk subgroups, and was specific for HER2 + :estrogen receptor alpha-negative (ERα − ) patients (10- + BC is caused by overexpression/amplification of the HER2/ERBB2/NEU tyrosine kinase receptor and constitutes 15-20% of cases. Approximately 50% of these are ERα + tumors, and 50% are ERα − . Current treatment of HER2 + BC involves chemotherapy plus trastuzumab (Herceptin; Genentech), a monoclonal antibody directed against HER2 (1) (2) (3) . Despite improvement in disease-free survival (DFS) over a 4-y follow-up (4), the cost of trastuzumab, adverse effects such as cardiac failure, and emergence of drug-resistance metastases represent serious limitations for its use, particularly in lowincome countries (5) . A prognostic signature that can predict clinical outcome from tumor biopsies at time of presentation may help prioritize patients for anti-HER2 therapy.
Because BC consists of several different subtypes, each with distinct pathological features and clinical behaviors, predictive prognostic signatures may need to be developed for each subtype.
In addition, many types of cancer exhibit hierarchical organization whereby only a fraction of cells, termed tumor-initiating cells (TICs), sustains growth, whereas the remaining tumor cells, which descend from TICs, have lost their tumorigenic potential (6) . HER2/Neu drives asymmetrical cell division, increases the frequency of TICs relative to mammary stem cells (7) , and its continuous expression is required to sustain tumorigenesis (8) . One strategy to identify prognostic signatures would be to base it on gene expression in enriched TIC populations for specific BC subtype. However, so far, most prognostic signatures for BC were generated irrespective of TICs or BC subtype. − Fraction. In this study, we used a mouse model of HER2 + BC, MMTV-Her2/Neu, which sprouts mammary tumors with similar characteristics as the human disease (13) . Previously, mammary TICs were identified in this model in the CD31
+ cell fraction at a frequency of ∼1/300 (14) . The cell surface markers CD49f, Sca-1, CD29, CD90, CD18 and CD14 failed to subdivide the CD24 + cell population for enrichment of TICs (14, 15) . We found that mechanical rather than enzymatic dissociation improved recovery of Her2/Neu TICs ∼3-fold to 1/84 (Fig. 1A) . As levels of the Notch-ligand Jagged1 (JAG1) can predict outcome in BC (16), we tested for expression of Jagged1 and its receptor Notch1 in lin − CD24 + cells by flow cytometry. Interestingly, both Jagged1 and Notch1 independently subdivided the CD24 + fraction into two populations (Fig. 1B) . Immunostaining of Neu tumors confirmed widespread expression of Jagged1 (Fig. 1C) .
To test whether these antigens could enrich TICs, tumor cells were sorted on the basis of CD24 plus JAG1 or Notch1 expression, serially diluted and transplanted into mammary glands of syngeneic mice. TIC frequency varied from tumor to tumor but was consistently higher in CD24 (17) . However, we found that HER2/NEU expression in four independent tumors was not statistically different in CD24 + : JAG1 + relative to CD24 + :JAG1 − cells (Fig. S1B ), indicating that JAG1 does not significantly affect HER2/NEU expression in this mouse model. It was previously reported that the MMTV-Her2/ Neu transgene, which encodes rat Her2/Neu (13, 18) , elicits immunorejection or immunoediting response in transplanted mice, leading to silencing of the transgene in secondary tumors (19) . However, secondary tumors expressed HER2 at comparable levels as primary tumors, and incidence of tumor formation was as high in isogenic immunocompetent recipient mice as in immunocompromised mice (Fig. S2) , Thus, at least following transplantation of a small number of lin − cells (≤50) the rat Her2/Neu transgene does not induce overt immunorejection in mice. To gain an insight into molecular regulations that determine Her2 + TIC function, we analyzed genes and pathways specifically expressed in TIC-enriched cell populations. Four independent MMTV-Neu primary mammary tumors (N250, N261, N283, N222/ N229) were harvested, lin − cells were sorted according to CD24 and JAG1 expression and subjected to gene expression microarray analysis. With the exception of CD24, which, as expected, was elevated in TICs, expression of several luminal markers was high and similar in TIC and non-TIC fractions, whereas expression of basal markers was generally low in both fractions (Fig. 3A) . (Fig. 3B) . Gene sets enriched in the TIC fraction included pathways associated with cell division; the non-TIC fraction was enriched in pathways associated with differentiation as well as immune response and angiogenesis.
Generation of a HTICS. To generate a Her2/Neu TIC-enriched prognostic signature, we analyzed publicly available cohorts with clinical outcomes and microarray expression data from RNA extracted from fresh tumor biopsies (Dataset S1A). Because HER2 status, as determined by immunostaining, was not available for most cohorts, we used twofold increase in expression of three or more of five genes on the HER2 amplicon (HER2/ErbB2, Stard3, Perld1, Grb7, C17orf37) as the basis to collate HER2 + patients. This criterion, previously used to generate HDPP (23), selected 69.5% of HER2 patients, as determined by IHC (Fig. S4) .
We first identified differentially expressed genes (329) that showed twofold or greater increase or decrease in enriched TIC versus non-TIC fractions with a significant P value (≤ 0.05). A total of 284 of these genes were found on a human overall survival (OS) cohort (GSE3143), which we used to train the signature. We classified patients using a "Score for Signature Match (SSM)" algorithm, modified from Ref. 9 (SI Material and Methods). Without training, the 284 genes could separate HER2 + patients in the GSE3143 cohort into poor and good prognosis groups with a HR of 2.54 (P = 0.072; Fig. S5A ). After testing for association and significance of each gene to patient outcome, a 40-gene signature was derived which could stratify patients with HR of 3.53 (P = 0.00742; Fig. S5A ). Further optimization resulted in a 17 Her2 TIC-enriched Signature, which we termed HTICS. Gene expression heat map of 45 HER2 + patients with descending SSM scores in the training cohort using HTICS is shown (Fig. 4A, Left) . A SSM > 0 cutoff was selected to evaluate its predictive power by Kaplan-Meier analysis. On this training cohort, tumors expressing HTICS had a reduced OS relative to tumors that did not express the signature (HR, 5.24; P = 0.000491; Fig. 4B ). HTICS was specific to HER2 + tumors; its predictive power for all BC subtypes or for HER2-negative tumors was statistically insignificant (Fig. S5B) .
HTICS consists of eight up-regulated (Aurkb, Ccna2, Scrn1, Npy, Atp7b, Chaf1b, Ccnb1, Cldn8) and nine down-regulated genes (Nrp1, Ccr2, C1qb, Cd74, Vcam1, Cd180, Itgb2, Cd72, St8sia4; Fig. 4B and Fig. S5C ). The up-regulated subset includes genes associated with passage through the S/G2/M phase of the cell cycle (Aurkb, cyclinB1, Cyclin A2; Chaf1b). Down-regulated in HTICS are genes involved in cell adhesion, angiogenesis and immune-response.
HTICS Predicts Clinical Outcome for HER2
+ :ERα − BC Patients Treated with Chemotherapy. We initially evaluated the prognostic power of HTICS using two metastasis-free survival (MFS) cohorts (n = 64) with annotated HER2 expression data determined by IHC. HTICS + patients exhibited poor MFS with HR of 2.62 relative to the HTICS-negative group (P = 0.043; Fig. 4C ). As MMTVNeu tumors are ERα-negative, we determined the effect of ERα-expression on the predictive power of HTICS. Remarkably, HTICS predicted 10-y MFS of 83.6% for signature-negative and 46.3% for signature-positive HER2 + :ERα − patients (HR, 9.64; P = 0.01), and was not predictive for the HER2 + :ERα + group (Fig. 4C, Upper) . Importantly, similar results were obtained when patients from these cohorts were collated on the basis of the fivegene HER2 amplicon, with MFS of 83.6% and 41.7% for HTICS − and HTICS + HER2 + :ERα − groups, respectively (HR, 10.24; P = 0.007; Fig. 4C, Lower) .
Next, we extended our analysis to other MFS, OS and DFS cohorts (excluding the training cohort) using the five-gene HER2 amplicon to identify HER2 + patients. HTICS predicted OS, MFS and DFS for HER2 + patients with HR of 2.1, 3, and 5.6, respectively (P < 0.002; Fig. 5A ). Moreover, for cohorts with available ERα data, HTICS predicted clinical outcomes for HER2 + :ERα − patients with a 10-y OS of 83.6% versus 24.0% (HR, 5.57; P = 0.002) and MFS of 90.9% versus 47.2% (H = 7.94; P = 0.00084) (Fig. 5 B and C) .
HTICS may identify patients with poor prognosis or poor response to chemotherapy. To address this question, we performed a retrospective analysis on cohorts of patients treated or not with conventional chemotherapy (Fig. S5D) The tumor suppressor p53 is a transcriptional activator of ERα; mutation in p53 correlates with reduced ERα expression and bad prognosis (24) . In a patient cohort with available p53 status (n = 32), the predictive power of HTICS was elevated in the p53 mutant arm (HR, 5.78; P = 0.0136) compared with the whole population (HR, 3.4; P = 0.028) or the p53 wild-type arm (HR, 2.34; P = 0.414; Fig. S5E ), suggesting that this signature can discriminate clinical outcome for HER2 + patients depending not only on ERα but also on p53 status.
+ :ERα − Patients: SDPP for HER2 + :ERα + . Next, we compared HTICS predictive power to other signatures (Dataset S1 C-N). The SDPP (12) was highly predictive for HER2 + BC patients (Fig. 5A ). This predictive power was proportional to the ERα + to ERα − ratio in these cohorts. Indeed, SDPP was not (OS, P = 0.794) or only moderately informative (MFS) (HR, 3.0; P < 0.02) for HER2 + :ERα − patients but was highly predictive for HER2 + :ERα + patients with a HR of 5.65 for OS (P ≤ 0.002) and HR, 4.21 (P < 0.01) for MFS (Fig. 5 B  and C) . Thus, together, HTICS and SDPP can be used to predict clinical outcome for the two HER2 + BC subtypes. For HER2 + : ERα + patients, a HER2-derived prognostic predictor (HDPP) (23) was also predictive for MFS better than HTICS with HR of 3.47 (P < 0.007; Fig. S6 ). In contrast, a 70-gene/mammaPrint (9), IGS (11), and BC proliferation signatures (25) (Fig. S6) . 
HTICS Predicts Clinical Outcome Independently of Other Predictors
Including Node Status. Next, we performed bi-and multivariate analyses of HER2 + and HER2 + :ERα − patients to determine the effect, if any, of chemotherapy, tumor grade, tumor size, age at detection and lymph node involvement on the prediction power of HTICS. HTICS was highly predictive independently of these other variables (Fig. S7) Fig. 6 and Fig. S8A ).
Whereas none of the HTICS − HER2 + :ERα − patients died during this 7.5-y period, all five patients who died had HTICS + tumors. However, because of the small size of the group and relatively short follow-up, the results were not statistically significant (P = 0.08; Fig. S8B) . A similar trend of poor prognosis was observed for MFS (Fig. S8B) .
To begin to assess benefits from trastuzumab, we retrospectively determined the fraction of HER2 + :ERα − patients that developed metastasis within 48 mo postsurgery in the publicly available trastuzumab-untreated (n = 33; Fig. 5C ) versus neoadjuvant chemotherapy/trastuzumab-treated patients (n = 27; Fig. 6A ). For HTICS − patients, trastuzumab did not have a significant effect with 2/15 (13%) developing metastasis in the trastuzumab-negative group versus 1/9 (11%) in the chemotherapy plus trastuzumab group (P = 0.873; Fig. 6B ). In contrast, for HTICS + patients, 12/18 (66%) relapsed in the chemotherapy group compared with 5/18 (27%) in the chemotherapy/trastuzumab group (Fig. 6B) . Despite the caveat of comparing independent patient cohorts, the results were highly significant (P = 0. patients benefit from trastuzumab and should be prioritized for anti-HER2 therapy.
Discussion
We report on the generation of a prognostic signature (HTICS) that can identify a high-risk HER2 + :ERα − BC subgroup, which, in retrospective analysis, resists chemotherapy but responds to chemotherapy plus trastuzumab. The signature was generated based on highly enriched TICs from a mouse model of HER2 + : ERα − BC. A critical step was to demonstrate by single cell transplantation assays that Her2 + TICs are similar and stable, hence analysis of a few primary tumors is broadly informative. Because the TIC-enriched fraction contains only a small percentage of TICS (2-4.6%), most cells in this fraction represent early progenitors with expression patterns that likely reflect the proportion of TICs in the tumor. Genes associated with the ability of a single cell to self renew and form a tumor at an otherwise normal site following transplantation into recipient mice, may also endow it with the ability to form micrometastases at distal sites and acquire the necessary genetic changes needed for full macrometastases in human (27) . Indeed, four of the eight up-regulated genes in HTICS are directly involved in cell cycle progression, DNA replication, and mitosis. In addition, HTICS includes down-regulated genes involved in immune response; this may allow TICs to evade immune surveillance, enhancing dissemination and metastasis.
In our retrospective analysis, chemotherapy plus trastuzumab treatment improved MFS 2.4-fold and OS 2.9-fold compared with trastuzumab-untreated therapy. Thus, HTICS can identify highrisk patients that may be prioritized for chemotherapy/trastuzumab therapy. This may be particularly relevant to low-income countries where trastuzumab therapy is not publicly available; HTICS + can provide an objective criterion and an incentive for signature-positive patients to undergo trastuzumab therapy. In contrast, the effect of trastuzumab on HTICS − patients was insignificant for both MFS and OS cohorts over a 4-y period. We stress that our results do not justify, at this stage, withholding trastuzumab therapy from HTICS − patients. A prospective analysis of large cohorts is urgently needed to assess small benefits, if any, of trastuzumab in this group. Clearly, the lack of large, prospective cohorts with clinical outcome and microarray data from RNA derived from fresh tumor biopsies is a major limitation. Large cohorts of formalin-fixed, paraffin-embedded BC tissues with clinical outcome are available. NanoString technology can be used to assess gene expression on paraffin-embedded specimens (28) . The application of this technology to large prospective cohorts of HER2 + :ERα − patients is now required to bring HTICS to the clinic.
Materials and Methods
Animal, histology, TIC analysis, the generation of HTICS, and Kaplan-Meier analysis were performed as described previously (14, 29) and SI Materials and Methods. TIC frequency was calculated using L-Calc software (StemCell Technologies). Microarray data were normalized using RMA method via Partek software. Score for Signature Match (SSM) was calculated using: SSM ¼ X ðI n X n =jX n jÞ= X ðjI n jÞ
Where I is gene index; 1 for up-regulated genes in TICs; −1 for down-regulated genes; X is log 2-transformed and median-centered gene expression value of the patient; n indicates signature gene number. SSM ≥0 was considered a match. Hazard ratios were calculated using COX proportional hazards survival regression. Heat maps and dendrograms were generated by JAVA tree-view.
